These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 24211253)
1. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. Li L; Wang J; Zhang Y; Zhang Y; Ma L; Weng W; Qiao Y; Xiao W; Wang H; Yu W; Pan Q; He Y; Sun F FEBS Lett; 2013 Dec; 587(24):3921-7. PubMed ID: 24211253 [TBL] [Abstract][Full Text] [Related]
2. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Wang J; Ma L; Weng W; Qiao Y; Zhang Y; He J; Wang H; Xiao W; Li L; Chu Q; Pan Q; Yu Y; Sun F Hepatology; 2013 Sep; 58(3):1011-20. PubMed ID: 23532963 [TBL] [Abstract][Full Text] [Related]
3. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Xiao W; Wang J; Ou C; Zhang Y; Ma L; Weng W; Pan Q; Sun F Biochem Biophys Res Commun; 2013 Sep; 439(2):167-72. PubMed ID: 23994632 [TBL] [Abstract][Full Text] [Related]
4. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma. Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697 [TBL] [Abstract][Full Text] [Related]
5. CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Yang N; Chen T; Wang L; Liu R; Niu Y; Sun L; Yao B; Wang Y; Yang W; Liu Q; Tu K; Liu Z Theranostics; 2020; 10(13):5790-5801. PubMed ID: 32483419 [No Abstract] [Full Text] [Related]
6. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer. Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671 [TBL] [Abstract][Full Text] [Related]
7. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation. Lin M; Zheng X; Yan J; Huang F; Chen Y; Ding R; Wan J; Zhang L; Wang C; Pan J; Cao X; Fu K; Lou Y; Feng XH; Ji J; Zhao B; Lan F; Shen L; He X; Qiu Y; Jin J Nat Commun; 2024 Jun; 15(1):4995. PubMed ID: 38862474 [TBL] [Abstract][Full Text] [Related]
8. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Xu MZ; Chan SW; Liu AM; Wong KF; Fan ST; Chen J; Poon RT; Zender L; Lowe SW; Hong W; Luk JM Oncogene; 2011 Mar; 30(10):1229-40. PubMed ID: 21076472 [TBL] [Abstract][Full Text] [Related]
9. NUAK2 is a critical YAP target in liver cancer. Yuan WC; Pepe-Mooney B; Galli GG; Dill MT; Huang HT; Hao M; Wang Y; Liang H; Calogero RA; Camargo FD Nat Commun; 2018 Nov; 9(1):4834. PubMed ID: 30446657 [TBL] [Abstract][Full Text] [Related]
10. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ. Zhu H; Yan F; Yuan T; Qian M; Zhou T; Dai X; Cao J; Ying M; Dong X; He Q; Yang B Cancer Res; 2020 Jun; 80(11):2204-2216. PubMed ID: 32217697 [TBL] [Abstract][Full Text] [Related]
11. Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways. Shi C; Cai Y; Li Y; Li Y; Hu N; Ma S; Hu S; Zhu P; Wang W; Zhou H Redox Biol; 2018 Apr; 14():59-71. PubMed ID: 28869833 [TBL] [Abstract][Full Text] [Related]
12. TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Wang J; Park JS; Wei Y; Rajurkar M; Cotton JL; Fan Q; Lewis BC; Ji H; Mao J Mol Cell; 2013 Jul; 51(2):211-25. PubMed ID: 23769673 [TBL] [Abstract][Full Text] [Related]
13. CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells. Lei L; Wu J; Gu D; Liu H; Wang S Tumour Biol; 2016 Aug; 37(8):11073-9. PubMed ID: 26906552 [TBL] [Abstract][Full Text] [Related]
14. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. Liu S; Miao R; Zhai M; Pang Q; Deng Y; Liu S; Qu K; Liu C; Zhang J Oncotarget; 2017 Jul; 8(29):47412-47424. PubMed ID: 28537892 [TBL] [Abstract][Full Text] [Related]
15. Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis. Zhu H; Wang DD; Yuan T; Yan FJ; Zeng CM; Dai XY; Chen ZB; Chen Y; Zhou T; Fan GH; Ying M; Cao J; Luo P; Liu XJ; Hu Y; Peng Y; He Q; Yang B Cancer Res; 2018 Jul; 78(14):3995-4006. PubMed ID: 29669759 [TBL] [Abstract][Full Text] [Related]
16. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Liu AM; Poon RT; Luk JM Biochem Biophys Res Commun; 2010 Apr; 394(3):623-7. PubMed ID: 20226166 [TBL] [Abstract][Full Text] [Related]
18. Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo. Kim MK; Park JY; Kang YN Pathol Res Pract; 2018 Jul; 214(7):1031-1039. PubMed ID: 29699904 [TBL] [Abstract][Full Text] [Related]
19. YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis. Thomann S; Weiler SME; Marquard S; Rose F; Ball CR; Tóth M; Wei T; Sticht C; Fritzsche S; Roessler S; De La Torre C; Ryschich E; Ermakova O; Mogler C; Kazdal D; Gretz N; Glimm H; Rempel E; Schirmacher P; Breuhahn K Cancer Res; 2020 Dec; 80(24):5502-5514. PubMed ID: 33087321 [TBL] [Abstract][Full Text] [Related]
20. Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis. Shu Y; Jin X; Ji M; Zhang Z; Wang X; Liang H; Lu S; Dong S; Lin Y; Guo Y; Zhuang Q; Wang Y; Lei Z; Guo L; Meng X; Zhou G; Zhang W; Chang L Cancer Res; 2024 Sep; 84(17):2836-2855. PubMed ID: 38862269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]